Literature DB >> 30390135

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.

Morten Alstrup1, Jeppe Meyer2, Martin Schultz3,2, Line Jee Hartmann Rasmussen2, Lars Simon Rasmussen4, Lars Køber5, Jakob Lundager Forberg6, Jesper Eugen-Olsen2, Kasper Iversen3.   

Abstract

BACKGROUND: Risk assessment strategies, such as using the American Society of Anesthesiologists (ASA) physical status classification, attempt to identify surgical high-risk patients. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker reflecting overall systemic inflammation and immune activation, and it could potentially improve the identification of high-risk surgical patients.
METHODS: We included patients acutely admitted to the emergency department who subsequently underwent surgery within 90 days of admission. Patients were stratified into low-risk or high-risk groups, according to ASA classification (ASAlow: ASA I-II; ASAhigh: ASA III-VI) and suPAR level, measured at admission (suPARhigh above and suPARlow below 5.5 ng/ml), respectively. Pre-specified complications were identified in national registries and electronic medical records. The association between ASA classification, suPAR level, CRP and the rate of postoperative complications was analyzed with logistic regression and Cox regression analyses, estimating odds ratios and hazard ratios (HRs).
RESULTS: During 90-day follow-up from surgery, 31 (7.0%) patients died and 158 (35.6%) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95% CI 1.6-4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001).
CONCLUSION: Measuring suPAR levels in acutely admitted patients may aid in identifying high-risk patients and improve prediction of postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30390135     DOI: 10.1007/s00268-018-4841-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  2 in total

1.  Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Athanasios Chalkias; Nikolaos Papagiannakis; Bernd Saugel; Moritz Flick; Konstantina Kolonia; Zacharoula Angelopoulou; Dimitrios Ragias; Dimitra Papaspyrou; Aikaterini Bouzia; Nicoletta Ntalarizou; Konstantinos Stamoulis; Aikaterini Kyriakaki; Jesper Eugen-Olsen; Eleni Laou; Eleni Arnaoutoglou
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making.

Authors:  Ria M Holstein; Marja T Mäkinen; Maaret K Castrén; Johanna M Kaartinen
Journal:  Biomark Insights       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.